{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:59:38Z","timestamp":1776844778737,"version":"3.51.2"},"reference-count":35,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:p>Since its first description more than a decade ago, our understanding of the clinical impact of hereditary alpha-tryptasemia has continued to evolve. First considered to be a genetic disorder with a subset of patients having a syndromic presentation composed of connective tissue abnormalities,\n symptoms of autonomic dysfunction, and findings of mast cell activation, we now know that hereditary alpha-tryptasemia is a common genetic trait and modifier of mast cell\u2010mediated reactions. More recent studies have shown some previously held associations with congenital hypermobility\n and postural orthostatic tachycardia syndrome (POTS) to be lacking, and illuminated previously unappreciated associations with clonal and nonclonal mast cell disorders. With the discovery of heterotetrameric tryptases and demonstration of their unique functional activities, the importance\n of tryptase gene composition in general has begun to take focus. Hereditary alpha-tryptasemia exists at the end of a spectrum of alpha-tryptase expression and as a natural overexpression model of this protein, brought to the fore the potential of tryptase genotyping as a genetic biomarker\n for anaphylaxis severity. These data and future studies hold the promise of enhancing our understanding of the role that tryptases play in health and disease.<\/jats:p>","DOI":"10.2500\/aap.2025.46.240088","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T04:30:58Z","timestamp":1735619458000},"page":"4-10","source":"Crossref","is-referenced-by-count":6,"title":["Appraisal of the evidence linking hereditary \u03b1-tryptasemia with mast cell disorders, hypermobility and dysautonomia"],"prefix":"10.2500","volume":"46","author":[{"given":"Jonathan J.","family":"Lyons","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"B2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.anai.2021.06.019","article-title":"Inherited and acquired determinants of serum tryptase levels in humans","volume":"127","author":"Lyons","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaci.2021.08.011","article-title":"On the complexities of tryptase genetics and impact on clinical phenotypes","volume":"148","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","article-title":"Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms","volume":"7","author":"Chovanec","year":"2023","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2021.42.210022","article-title":"The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome","volume":"42","author":"Wang","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jaip.2022.05.003","article-title":"Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions","volume":"10","author":"Lyons","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-030-27820-5_3","article-title":"Clinical approach to a patient with elevated serum tryptase: implications of acute versus basally elevated levels","volume-title":"Mastocytosis","author":"Lyons","year":"2020"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.4049\/jimmunol.138.8.2611","article-title":"Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells","volume":"138","author":"Schwartz","year":"1987","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jaci.2022.04.025","article-title":"Differential mast cell mediators in systemic mastocytosis and hereditary \u03b1-tryptasemia","volume":"150","author":"Giannetti","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jaip.2018.01.006","article-title":"Diagnostic value of tryptase in food allergic reactions: a prospective study of 160 adult peanut challenges","volume":"6","author":"Dua","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2023.07.014","article-title":"Severe food allergy reactions are associated with \u03b1-tryptase","volume":"152","author":"Lang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/all.16109","article-title":"Mast cell activation identified through urine mediators","volume":"79","author":"Giannetti","year":"2024","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0091-6749(05)80147-2","article-title":"Determination of N-methylhistamine in urine as an indicator of histamine release in immediate allergic reactions","volume":"86","author":"Stephan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jaip.2023.02.017","article-title":"Increased excretion of mast cell mediator metabolites during mast cell activation syndrome","volume":"11","author":"Butterfield","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","author":"Chollet","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B20","article-title":"Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals","author":"Gonzalez-de-Olano","year":"2023","journal-title":"Allergy"},{"key":"B21","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","author":"Greiner","year":"2020","journal-title":"Blood"},{"key":"B22","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","author":"Lyons","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2023.08.015","article-title":"Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes","volume":"153(1)","author":"Polivka","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2022.09.038","article-title":"Disease correlates and clinical relevance of hereditary alpha-tryptasemia in patients with systemic mastocytosis","volume":"151(2)","author":"Sordi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11882-024-01136-y","article-title":"Alpha-tryptase as a risk-modifying factor for mast cell-mediated reactions","volume":"24","author":"Shin","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"B26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis.","volume":"14:137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1111\/all.16185","article-title":"A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma","author":"Madrange","year":"2024","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaci.2021.02.043","article-title":"Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone","volume":"148","author":"\u0160elb","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/all.16084","article-title":"High burden of clonal mast cell disorders and hereditary \u03b1-tryptasemia in patients who need Hymenoptera venom immunotherapy","volume":"79","author":"Koro\u0161ec","year":"2024","journal-title":"Allergy"},{"key":"B31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/all.15911","article-title":"Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals","volume":"79","author":"Gonz\u00e1lez\u2010de\u2010Olano","year":"2023","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"B33","first-page":"100094","article-title":"Hereditary alpha-tryptasemia modifies clinical phenotypes among individuals with congenital hypermobility disorders","volume":"3","author":"Vazquez","year":"2022","journal-title":"HGG Adv"},{"key":"B34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaip.2023.10.043","article-title":"Hereditary alpha-tryptasemia in patients with postural orthostatic tachycardia syndrome","volume":"12","author":"Huang","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000001\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T04:32:41Z","timestamp":1735705961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.240088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["1088-5412(20250101)46:1L.4;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.240088","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}